Two injections, two completely different jobs

If you've been told you have knee cartilage damage and someone has mentioned both ChondroFiller and a steroid injection, the first thing worth knowing is that these two treatments are not competing versions of the same idea. They do fundamentally different jobs.

ChondroFiller® Liquid is a biological collagen scaffold — an injectable matrix placed into the damaged area of cartilage to support the body's own structural repair processes. A corticosteroid injection delivers a potent anti-inflammatory drug into the joint to damp down pain and swelling quickly. One targets the tissue deficit; the other targets the inflammatory response sitting on top of it.

Neither is universally the better option. The practical question is what the patient is trying to achieve: rapid symptom relief, or addressing the underlying cartilage defect over time. Those are different clinical goals, and they point in different directions.

Both treatments are delivered as ultrasound-guided outpatient injections — the difference lies not in how they are given, but in what each does once it is inside the joint.

How ChondroFiller works inside the joint

Once the collagen solution is placed inside the cartilage defect, it self-gels within minutes — forming a stable, three-dimensional scaffold that fills the damaged area. ChondroFiller® Liquid is a CE-marked Class III medical device made from natively extracted murine Type I collagen; the gelation happens in situ, without additional steps after injection.

What follows is a process called acellular matrix-induced chondrogenesis. The scaffold acts as a chemotactic signal, recruiting the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — into the defect site. No donor cells are introduced at any point; the product is acellular. Instead, the implanted matrix creates the conditions for the body's biology to populate the space, with recruited cells differentiating to support tissue regeneration as the collagen scaffold gradually degrades and is replaced.

Clinical data from the manufacturer's Clinical Evaluation Report documents an average IKDC score improvement of approximately 30 points over 12 months — a threshold widely regarded as clinically meaningful for knee function. MRI fill assessment using MOCART scoring has reached 70–87, indicating structural integration within the defect.

More than 20,000 implantations have been performed across ten-plus years of CE-marked use, with a complaint rate of approximately 0.06% — a reassuring real-world safety profile for patients weighing a relatively newer biological therapy against more familiar options.

What corticosteroid injection does — and what it does not

Corticosteroids — most commonly methylprednisolone or triamcinolone — are well-established in joint medicine precisely because they work quickly. Injected into the knee, they damp the inflammatory response within days, producing meaningful reductions in pain and swelling for many patients. That speed has real value in the right situation: managing an acute flare that is preventing rehabilitation, reducing joint inflammation ahead of a planned procedure, or helping to confirm that inflammation — rather than mechanical factors — is the primary driver of a patient's symptoms.

The limitation is duration. Corticosteroids do not alter joint biology; they suppress inflammation for as long as the drug is present. As it is metabolised over weeks to months, symptoms typically return. A landmark RCT published in the New England Journal of Medicine (Deyle et al., 2020) found physical therapy comparable to, or superior to, glucocorticoid injection for knee osteoarthritis over medium-term follow-up — evidence that steroid benefit, while genuine, does not persist.

There is no structural component to the effect. Corticosteroid does not fill a cartilage defect, lay down a scaffold, or stimulate tissue regeneration of any kind. For patients whose primary concern is the underlying defect, that distinction is directly relevant.

The key clinical question is whether short-term symptom relief is what the situation actually calls for — because where that is the need, corticosteroid injection delivers it reliably, within a defined and time-limited window.

Chondrotoxicity: the risk steroids carry for damaged cartilage

Two independent lines of peer-reviewed evidence document direct harm to articular cartilage from corticosteroid exposure. Wernecke, Braun and Dragoo's 2015 systematic review in the Orthopaedic Journal of Sports Medicine identified chondrotoxic effects from intra-articular corticosteroids; Dragoo et al.'s companion study (Knee Surgery, Sports Traumatology, Arthroscopy, 2012) found this harm demonstrable from a single dose — not only from repeated use. A randomised controlled trial by McAlindon and colleagues, published in JAMA in 2017, added a longitudinal dimension: patients receiving repeated triamcinolone injections over two years showed greater cartilage volume loss than those given placebo.

For a patient who already has focal cartilage damage, that body of evidence warrants careful consideration. Repeated steroid injections in an already-compromised joint may accelerate the deterioration the patient is trying to avoid — a documented signal in peer-reviewed literature, not a theoretical projection. Cumulative exposure also increases the risk of tendon injury and, where arthroscopic procedures follow within a short interval, raises infection risk.

Context makes an important difference, however. A single corticosteroid injection given to control acute inflammation ahead of a planned procedure, or to help clarify the diagnostic picture, carries a meaningfully different risk profile from a course of repeated injections over months or years. The clinical concern concentrates where repetition is involved and where the cartilage is already under structural threat — precisely the situation many patients reading this will recognise.

What the evidence actually shows — and where it is thin

Taken together, the evidence for these two treatments tells a story of asymmetry rather than equivalence. ChondroFiller's clinical data — principally manufacturer-sponsored investigations and small independent case series — establishes clinically meaningful functional gains and structural integration, but without a large independent RCT against an active comparator. Corticosteroids carry a broader and more diverse evidence base for symptom relief, accumulated over decades — yet that same literature increasingly documents a chondrotoxicity signal and limited durability in patients with existing cartilage pathology.

The critical absence is any head-to-head comparative trial. That absence belongs to the field rather than to either product: regenerative cartilage scaffolds and pharmacological anti-inflammatories have not been studied against each other in a formally designed RCT. The practical consequence is that superiority claims in either direction cannot be sustained — only evidence-anchored trade-offs.

For patients, the asymmetry is where the evidence becomes useful. ChondroFiller's efficacy data is drawn from a narrower study base, but its post-market safety record across real-world clinical use provides a substantive signal that the intervention is not doing harm at scale. Corticosteroid's symptom evidence is well-established, but carries a specific caveat for anyone whose primary concern is cartilage preservation. A structural defect and an inflammatory flare call for different types of evidence — and these two treatments provide exactly that.

Which option fits your situation

Three patient profiles tend to clarify the choice more usefully than a general principle.

If the goal is addressing a structural cartilage deficit — confirmed focal damage, symptoms not solely driven by an acute inflammatory flare, and a preference for a treatment that supports the body's own repair processes — ChondroFiller's injectable collagen scaffold pathway is the more relevant direction. Crucially, it carries no upper age limit and no defect-size ceiling, which means patients told they are too old or too far advanced for surgical cartilage procedures are not automatically excluded from an assessment.

If short-term inflammation control is the immediate need — during an acute flare, or in the weeks before a planned procedure — a corticosteroid injection has a well-defined and legitimate role in that specific context. Where existing cartilage damage is present and repeated steroid injections have already been given, however, the chondrotoxicity evidence makes a structured clinical reassessment more valuable than another automatic repeat.

The two approaches are not automatically mutually exclusive in all circumstances, but whether there is any combined role in a given case is a clinical question — one that requires imaging, a detailed history, and consultant-led judgement.

MSK Doctors provides that kind of structured assessment at Sleaford (NG34) and Grantham (NG31), with no GP referral needed — making it a direct route to the clinical evaluation this decision genuinely warrants. Appointments can be booked at mskdoctors.com.

1. [1] Corticosteroid. https://en.wikipedia.org/?curid=57996 https://en.wikipedia.org/?curid=57996
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351